Upregulation of RCAN1 causes down syndrome-like immune dysfunction

Journal of Medical Genetics

Volumn 50, Issue 7, 2013, Pages 444-454

  Martin, Katherine R ^a   Layton, Daniel ^a   Seach, Natalie ^a   Corlett, Alicia ^a   Barallobre, Maria Jose ^b   Arbonés, Maria L ^b,c   Boyd, Richard L ^a   Scott, Bernadette ^a   Pritchard, Melanie A ^a  

^a MONASH UNIVERSITY   (Australia)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; REGULATOR OF CALCINEURIN 1; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN SYNDROME; EPITHELIUM; FLOW CYTOMETRY; IMMUNE DYSREGULATION; LYMPH NODE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; STEM CELL; STROMA CELL; T LYMPHOCYTE; THYMUS; UPREGULATION; WILD TYPE;

MUS; MUS MUSCULUS;

EID: 84883202984     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmedgenet-2013-101522     Document Type: Article

References (48)

1. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 2002;359:1019-25.
2. Chistiakov D. Down syndrome and coexistent autoimmune diseases. J Appl Biomed 2007;5:71-6.
3. Kusters MA, Verstegen RH, Gemen EF, de Vries E. Intrinsic defect of the immune system in children with Down syndrome: a review. Clin Exp Immunol 2009;156:189-93.
4. de Hingh YC, van der Vossen PW, Gemen EF, Mulder AB, Hop WC, Brus F, de Vries E. Intrinsic abnormalities of lymphocyte counts in children with down syndrome. J Pediatr 2005;147:744-7.
5. Levin S, Schlesinger M, Handzel Z, Hahn T, Altman Y, Czernobilsky B, Boss J. Thymic deficiency in Down's syndrome. Pediatrics 1979;63:80-7.
6. Anderson G, Jenkinson EJ. Lymphostromal interactions in thymic development and function. Nat Rev Immunol 2001;1:31-40.
7. Boyd RL, Tucek CL, Godfrey DI, Izon DJ, Wilson TJ, Davidson NJ, Bean AG, Ladyman HM, Ritter MA, Hugo P. The thymic microenvironment. Immunol Today 1993;14:445-59.
8. Petrie HT. Role of thymic organ structure and stromal composition in steady-state postnatal T-cell production. Immunol Rev 2002;189:8-19.
9. Klug DB, Carter C, Crouch E, Roop D, Conti CJ, Richie ER. Interdependence of cortical thymic epithelial cell differentiation and T-lineage commitment. Proc Natl Acad Sci U S A 1998;95:11822-7.
10. Klug DB, Carter C, Gimenez-Conti IB, Richie ER. Cutting edge: thymocyte-independent and thymocyte-dependent phases of epithelial patterning in the fetal thymus. J Immunol 2002;169:2842-5.
11. Palmer DB, Viney JL, Ritter MA, Hayday AC, Owen MJ. Expression of the alpha beta T-cell receptor is necessary for the generation of the thymic medulla. Dev Immunol 1993;3:175-9.
12. van Ewijk W, Hollander G, Terhorst C, Wang B. Stepwise development of thymic microenvironments in vivo is regulated by thymocyte subsets. Development 2000;127:1583-91.
13. van Ewijk W, Wang B, Hollander G, Kawamoto H, Spanopoulou E, Itoi M, Amagai T, Jiang YF, Germeraad WT, Chen WF, Katsura Y. Thymic microenvironments, 3-D versus 2-D?. Semin Immunol 1999;11:57-64.
14. Murphy M, Epstein LB. Down syndrome (trisomy 21) thymuses have a decreased proportion of cells expressing high levels of TCR alpha, beta and CD3. A possible mechanism for diminished T cell function in Down syndrome. Clin Immunol Immunopathol 1990;55:453-67.
15. Nespoli L, Burgio GR, Ugazio AG, Maccario R. Immunological features of Down's syndrome: a review. J Intellect Disabil Res 1993;37(Pt 6):543-51.
16. Whittingham S, Pitt DB, Sharma DL, Mackay IR. Stress deficiency of the T-lymphocyte system exemplified by Down syndrome. Lancet 1977;1:163-6.
17. Bertotto A, Crupi S, Arcangeli C, Gerli R, Scalise F, Fabietti G, Agea E, Vaccaro R. T-cell response to phorbol ester PMA and calcium ionophore A23187 in Down's syndrome. Scand J Immunol 1989;30:583-6.
18. Franciotta D, Verri A, Zardini E, Andreoni L, De Amici M, Moratti R, Nespoli L. Interferon-gamma- and interleukin-4-producing T cells in Down's syndrome. Neurosci Lett 2006;395:67-70.
19. Gerez L, Madar L, Arad G, Sharav T, Reshef A, Ketzinel M, Sayar D, Silberberg C, Kaempfer R. Aberrant regulation of interleukin-2 but not of interferon-gamma gene expression in Down syndrome (trisomy 21). Clin Immunol Immunopathol 1991;58:251-66.
20. Murphy M, Friend DS, Pike-Nobile L, Epstein LB. Tumor necrosis factor-alpha and IFN-gamma expression in human thymus. Localization and overexpression in Down syndrome (trisomy 21). J Immunol 1992;149:2506-12.
21. Ermak G, Morgan TE, Davies KJ. Chronic overexpression of the calcineurin inhibitory gene DSCR1 (Adapt78) is associated with Alzheimer's disease. J Biol Chem 2001;276:38787-94.
22. Fuentes JJ, Genesca L, Kingsbury TJ, Cunningham KW, Perez-Riba M, Estivill X, de la Luna S. DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. Hum Mol Genet 2000;9:1681-90.
23. Fuentes JJ, Pritchard MA, Planas AM, Bosch A, Ferrer I, Estivill X. A new human gene from the Down syndrome critical region encodes a proline-rich protein highly expressed in fetal brain and heart. Hum Mol Genet 1995;4:1935-44.
24. Kingsbury TJ, Cunningham KW. A conserved family of calcineurin regulators. Genes Dev 2000;14:1595-604.
25. Rothermel B, Vega RB, Yang J, Wu H, Bassel-Duby R, Williams RS. A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling. J Biol Chem 2000;275:8719-25.
26. Rothermel BA, McKinsey TA, Vega RB, Nicol RL, Mammen P, Yang J, Antos CL, Shelton JM, Bassel-Duby R, Olson EN, Williams RS. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A 2001;98:3328-33.
27. Ryeom S, Greenwald RJ, Sharpe AH, McKeon F. The threshold pattern of calcineurin-dependent gene expression is altered by loss of the endogenous inhibitor calcipressin. Nat Immunol 2003;4:874-81.
28. Vega RB, Rothermel BA, Weinheimer CJ, Kovacs A, Naseem RH, Bassel-Duby R, Williams RS, Olson EN. Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy. Proc Natl Acad Sci U S A 2003;100:669-74.
29. Vega RB, Yang J, Rothermel BA, Bassel-Duby R, Williams RS. Multiple domains of MCIP1 contribute to inhibition of calcineurin activity. J Biol Chem 2002;277:30401-7.
30. Perrino BA, Ng LY, Soderling TR. Calcium regulation of calcineurin phosphatase activity by its B subunit and calmodulin. Role of the autoinhibitory domain. J Biol Chem 1995;270:7012.
31. Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 2003;17:2205-32.
32. Keating DJ, Dubach D, Zanin MP, Yu Y, Martin K, Zhao YF, Chen C, Porta S, Arbones ML, Mittaz L, Pritchard MA. DSCR1/RCAN1 regulates vesicle exocytosis and fusion pore kinetics: implications for Down syndrome and Alzheimer's disease. Hum Mol Genet 2008;17:1020-30.
33. Hoeffer CA, Dey A, Sachan N, Wong H, Patterson RJ, Shelton JM, Richardson JA, Klann E, Rothermel BA. The Down syndrome critical region protein RCAN1 regulates long-term potentiation and memory via inhibition of phosphatase signaling. J Neurosci 2007;27:13161-72.
34. Gray DH, Fletcher AL, Hammett M, Seach N, Ueno T, Young LF, Barbuto J, Boyd RL, Chidgey AP. Unbiased analysis, enrichment and purification of thymic stromal cells. J Immunol Methods 2008;329:56-66.
35. Shioda N, Moriguchi S, Shirasaki Y, Fukunaga K. Generation of constitutively active calcineurin by calpain contributes to delayed neuronal death following mouse brain ischemia. J Neurochem 2006;98:310-20.
36. Wu HY, Tomizawa K, Oda Y, Wei FY, Lu YF, Matsushita M, Li ST, Moriwaki A, Matsui H. Critical role of calpain-mediated cleavage of calcineurin in excitotoxic neurodegeneration. J Biol Chem 2004;279:4929-40.
37. Martin KR, Corlett A, Dubach D, Mustafa T, Coleman HA, Parkington HC, Merson TD, Bourne JA, Porta S, Arbones ML, Finkelstein DI, Pritchard MA. Over-expression of RCAN1 causes Down syndrome-like hippocampal deficits that alter learning and memory. Hum Mol Genet 2012;21:3025-41.
38. Verstegen RH, Kusters MA, Gemen EF, DEV E. Down syndrome B-lymphocyte subpopulations, intrinsic defect or decreased T-lymphocyte help. Pediatr Res 2010;67:563-9.
39. Bains I, Antia R, Callard R, Yates AJ. Quantifying the development of the peripheral naive CD4+ T-cell pool in humans. Blood 2009;113:5480-7.
40. Bloemers BL, Bont L, de Weger RA, Otto SA, Borghans JA, Tesselaar K. Decreased thymic output accounts for decreased naive T cell numbers in children with Down syndrome. J Immunol 2011;186:4500-7.
41. Grusby MJ, Glimcher LH. Immune responses in MHC class II-deficient mice. Annu Rev Immunol 1995;13:417-35.
42. Grusby MJ, Johnson RS, Papaioannou VE, Glimcher LH. Depletion of CD4+ T cells in major histocompatibility complex class II-deficient mice. Science 1991;253:1417-20.
43. Teh HS, Kisielow P, Scott B, Kishi H, Uematsu Y, Bluthmann H, von Boehmer H. Thymic major histocompatibility complex antigens and the alpha beta T-cell receptor determine the CD4/CD8 phenotype of T cells. Nature 1988;335:229-33.
44. Cosgrove D, Gray D, Dierich A, Kaufman J, Lemeur M, Benoist C, Mathis D. Mice lacking MHC class II molecules. Cell 1991;66:1051-66.
45. Grusby MJ, Auchincloss H Jr, Lee R, Johnson RS, Spencer JP, Zijlstra M, Jaenisch R, Papaioannou VE, Glimcher LH. Mice lacking major histocompatibility complex class I and class II molecules. Proc Natl Acad Sci U S A 1993;90:3913-17.
46. Takaki T, Hosaka N, Miyake T, Cui W, Nishida T, Inaba M, Ikehara S. Presence of donor-derived thymic epithelial cells in [B6→MRL/lpr] mice after allogeneic intra-bone marrow-bone marrow transplantation (IBM-BMT). J Autoimmun 2008;31:408-15.
47. Mackay IR, Leskovsek NV, Rose NR. The odd couple: a fresh look at autoimmunity and immunodeficiency. J Autoimmun 2010;35:199-205.
48. Bush E, Fielitz J, Melvin L, Martinez-Arnold M, McKinsey TA, Plichta R, Olson EN. A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway. Proc Natl Acad Sci U S A 2004;101:2870-5